[go: up one dir, main page]

CY1114118T1 - Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη - Google Patents

Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη

Info

Publication number
CY1114118T1
CY1114118T1 CY20131100384T CY131100384T CY1114118T1 CY 1114118 T1 CY1114118 T1 CY 1114118T1 CY 20131100384 T CY20131100384 T CY 20131100384T CY 131100384 T CY131100384 T CY 131100384T CY 1114118 T1 CY1114118 T1 CY 1114118T1
Authority
CY
Cyprus
Prior art keywords
lurasidoni
pharmaceutical compositions
compositions containing
active ingredient
water soluble
Prior art date
Application number
CY20131100384T
Other languages
English (en)
Inventor
K Fujihara
Original Assignee
Dainippon Sumitomo Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114118(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dainippon Sumitomo Pharma Co., Ltd. filed Critical Dainippon Sumitomo Pharma Co., Ltd.
Publication of CY1114118T1 publication Critical patent/CY1114118T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ένα παρασκεύασμα για στοματική χορήγηση που περιέχει: προζελατινοποιημένο άμυλο που περιέχει υδροχλωρικό άλας Ν-[4-[4-(1,2-βενζισοθειαζολ-3-υλο)-1-πιπεραζινυλο]-(2R,3R)-2,3-τετραμεθυλενοβουτυλο]-(1'R,2'S,3'R,4'S)-2,3-δικυκλο[2,2,1]επτανοδικαρβοξυιμίδιου (λουρασιδόνη) που παριστάνεται στον τύπο (1) ως ενεργό συστατικό, υδατοδιαλυτό έκδοχο και υδατοδιαλυτό πολυμερές συνδετικό, το οποίο παρασκεύασμα εμφανίζει αμετάβλητο επίπεδο συμπεριφοράς έκλουσης ακόμα και όταν η περιεκτικότητα του σε ενεργό συστατικό ποικίλει.
CY20131100384T 2005-05-26 2013-05-14 Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη CY1114118T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005153508 2005-05-26
EP06746900.7A EP1884242B1 (en) 2005-05-26 2006-05-26 Pharmaceutical composition comprising lurasidone

Publications (1)

Publication Number Publication Date
CY1114118T1 true CY1114118T1 (el) 2016-06-22

Family

ID=37452103

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100384T CY1114118T1 (el) 2005-05-26 2013-05-14 Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
CY2014039C CY2014039I2 (el) 2005-05-26 2014-09-18 Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2014039C CY2014039I2 (el) 2005-05-26 2014-09-18 Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη

Country Status (21)

Country Link
US (5) US8729085B2 (el)
EP (2) EP1884242B1 (el)
JP (2) JP4733120B2 (el)
KR (2) KR101552033B1 (el)
CN (2) CN101184489B (el)
AU (1) AU2006250340C1 (el)
BR (2) BR122020005056B1 (el)
CA (1) CA2606510C (el)
CY (2) CY1114118T1 (el)
DK (2) DK1884242T3 (el)
ES (2) ES2408687T3 (el)
FR (1) FR14C0069I2 (el)
HU (1) HUS1400051I1 (el)
LU (1) LU92550I2 (el)
MX (1) MX2007014872A (el)
NL (1) NL300690I2 (el)
PL (1) PL1884242T3 (el)
PT (1) PT1884242E (el)
RU (1) RU2398586C3 (el)
SI (1) SI1884242T1 (el)
WO (1) WO2006126681A1 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101180046B (zh) * 2005-05-18 2011-12-28 大日本住友制药株式会社 含有屈昔多巴的稳定片剂
CN101184489B (zh) * 2005-05-26 2011-01-19 大日本住友制药株式会社 药物组合物
CA2714524A1 (en) * 2008-02-11 2009-08-20 Makiko Yanagida Tablet having improved elution properties
JP5583012B2 (ja) * 2008-06-13 2014-09-03 大日本住友製薬株式会社 口腔内速崩壊錠及びその製造方法
CN102170912A (zh) * 2008-09-30 2011-08-31 大洋药品工业株式会社 压缩成型制剂及其制造方法
DK2391355T3 (en) 2009-05-19 2017-02-27 Celgene Corp FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION
EP2629775A4 (en) 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
US9433620B2 (en) * 2011-05-13 2016-09-06 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
WO2013061338A1 (en) 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (zh) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 一种口服片剂及其制备方法和用途
CN102688209A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮片和制备方法
CN102688210A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮的药物组合物和制备方法
CN103536568B (zh) * 2012-07-12 2016-12-07 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) * 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
WO2018083117A1 (en) * 2016-11-02 2018-05-11 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral pharmaceutical compositions of lurasidone hydrochloride
CN108567758A (zh) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 盐酸鲁拉西酮片剂及其制备方法
MX2020001877A (es) * 2017-08-18 2020-09-14 Abbvie Inc Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis.
CN107875122A (zh) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮口崩片及其制备方法
WO2019167978A1 (ja) 2018-02-28 2019-09-06 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
PL3772992T3 (pl) 2018-04-10 2022-10-31 Freshfoodz Gmbh Sposób konserwowania posiłku przygotowanego przez podgrzewanie i dostarczania żywienia zbiorowego
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
CA3153004A1 (en) * 2019-09-25 2021-04-01 Nobelpharma Co., Ltd. Granule having masked unpleasant taste and method for producing same
WO2022042646A1 (zh) * 2020-08-26 2022-03-03 浙江华海药业股份有限公司 盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
AU2021410896A1 (en) * 2020-12-23 2023-06-29 Alphanavi Pharma Inc. Oral solid preparation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CA2213700C (en) 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
JP4022269B2 (ja) 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
HUP0004132A3 (en) 1997-10-20 2006-06-28 Dainippon Sumitomo Pharma Co Rapidly soluble drug composition
JP4063386B2 (ja) * 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 速放性経口医薬品組成物
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
WO2001076557A1 (en) * 2000-04-10 2001-10-18 Sumitomo Pharmaceuticals Co., Ltd. Sustained release preparations
ES2325764T3 (es) * 2000-09-22 2009-09-16 Dainippon Sumitomo Pharma Co., Ltd. Preparaciones orales con buenas caracteristicas de desintegracion.
TWI258469B (en) 2001-03-19 2006-07-21 Dainippon Pharmaceutical Co Aryl-substituted alicyclic compounds and pharmaceutical composition containing the same
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AU2003257589A1 (en) * 2002-08-22 2004-03-11 Sumitomo Pharmaceuticals Company, Limited Remedy for integration dysfunction syndrome
AU2003304236A1 (en) 2002-08-30 2005-01-13 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
JPWO2004078173A1 (ja) * 2003-02-05 2006-06-08 塩野義製薬株式会社 溶出性の改善された錠剤
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
KR20060126688A (ko) 2003-12-09 2006-12-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 약물-함유 입자 및 그 입자를 함유하는 고형 제제
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CN101184489B (zh) 2005-05-26 2011-01-19 大日本住友制药株式会社 药物组合物

Also Published As

Publication number Publication date
BR122020005056A8 (pt) 2022-11-22
EP2422783B1 (en) 2015-04-08
KR20130122019A (ko) 2013-11-06
US20150056284A1 (en) 2015-02-26
KR101552033B1 (ko) 2015-09-09
US20150265611A1 (en) 2015-09-24
AU2006250340A1 (en) 2006-11-30
US20090143404A1 (en) 2009-06-04
LU92550I2 (fr) 2015-11-02
DK2422783T3 (en) 2015-05-11
PL1884242T3 (pl) 2013-09-30
NL300690I2 (nl) 2017-11-02
CN101184489B (zh) 2011-01-19
CN101184489A (zh) 2008-05-21
BRPI0611409A2 (pt) 2010-11-23
JP2011126915A (ja) 2011-06-30
KR101380088B1 (ko) 2014-04-10
US8729085B2 (en) 2014-05-20
HUS1400051I1 (hu) 2016-10-28
CY2014039I1 (el) 2016-06-22
CY2014039I2 (el) 2016-06-22
FR14C0069I2 (fr) 2015-11-20
AU2006250340B2 (en) 2012-02-09
CN102048734B (zh) 2013-11-20
RU2398586C2 (ru) 2010-09-10
US20180161322A1 (en) 2018-06-14
DK1884242T3 (da) 2013-05-06
EP1884242A4 (en) 2009-07-01
ES2408687T3 (es) 2013-06-21
PT1884242E (pt) 2013-05-21
CA2606510C (en) 2014-07-22
RU2398586C3 (ru) 2017-10-04
HK1108379A1 (en) 2008-05-09
BR122020005056B1 (pt) 2023-01-10
US20140235651A1 (en) 2014-08-21
WO2006126681A1 (ja) 2006-11-30
EP2422783A1 (en) 2012-02-29
US9907794B2 (en) 2018-03-06
MX2007014872A (es) 2008-02-15
EP1884242B1 (en) 2013-04-17
EP1884242A1 (en) 2008-02-06
JPWO2006126681A1 (ja) 2008-12-25
BR122020005056A2 (el) 2010-11-23
KR20080012306A (ko) 2008-02-11
SI1884242T1 (sl) 2013-07-31
CN102048734A (zh) 2011-05-11
US9555027B2 (en) 2017-01-31
BRPI0611409B8 (pt) 2021-05-25
BRPI0611409A8 (pt) 2015-12-15
AU2006250340C1 (en) 2014-06-12
CA2606510A1 (en) 2006-11-30
BRPI0611409B1 (pt) 2020-12-29
JP4733120B2 (ja) 2011-07-27
FR14C0069I1 (fr) 2014-10-24
ES2535478T3 (es) 2015-05-12
RU2007148997A (ru) 2009-07-10
US8883794B2 (en) 2014-11-11
JP5285105B2 (ja) 2013-09-11

Similar Documents

Publication Publication Date Title
CY1114118T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
RU2458920C2 (ru) Новые соединения
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
MA31432B1 (fr) Metabolites de derives de (thio) carbamoyl-cyclohexane
CY1112646T1 (el) Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1α
PE20121314A1 (es) Derivados de 4-aminociclohexano sustituido
EA200870489A1 (ru) Пиперидинилзамещённые пирролидиноны в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы 1
BR122013033343B8 (pt) dimaleato de 4-[(3-cloro-4-fluorfenil)amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il]amino}-7-((s)-tetraidrofuran-3-ilóxi)-quinazolina, seu uso e seu processo de preparação, e composições farmacêuticas
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BR0214342A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
BRPI0411603A (pt) 4-(aminometil)-piperidina benzamidas como antagonistas 5ht4
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
ATE501121T1 (de) 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate